Inventor · disambiguated record
Michael Karl Bechtold
Also filed as: BECHTOLD MICHAEL KARL
6 granted patents·7 pending applications·29 citations·filing 2009–2024
81Inventor score
Top patents by PatentIndex Score
13 records- 0196US11633396B2Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-oneKUDOS PHARM LTD·Filed 2022·Granted Apr 25, 2023·8 cites·30 claims
- 0290US12178816B2Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-oneKUDOS PHARM LTD·Filed 2024·Granted Dec 31, 2024·0 cites·30 claims
- 0390US12144810B1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-oneKUDOS PHARM LTD·Filed 2024·Granted Nov 19, 2024·0 cites·30 claims
- 0490US8475842B2Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-oneBECHTOLD MICHAEL KARL·Filed 2009·Granted Jul 2, 2013·21 cites·10 claims
- 0586US12048695B2Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-oneKUDOS PHARM LTD·Filed 2023·Granted Jul 30, 2024·0 cites·10 claims
- 0686US11975001B2Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-oneKUDOS PHARM LTD·Filed 2023·Granted May 7, 2024·0 cites·13 claims
- 0778US2022249474A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneKUDOS PHARM LTD·Filed 2021·Application pending·0 cites
- 0872US2020323847A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneASTRAZENECA UK LTD·Filed 2020·Application pending·0 cites
- 0969US2019365751A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneASTRAZENECA UK LTD·Filed 2018·Application pending·0 cites
- 1065US2018133216A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneASTRAZENECA UK LTD·Filed 2017·Application pending·0 cites
- 1164US2017173010A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneASTRAZENECA UK LTD·Filed 2017·Application pending·0 cites
- 1263US2014066447A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneASTRAZENECA UK LTD·Filed 2013·Application pending·0 cites
- 1358US2016008473A1Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-oneASTRAZENECA UK LTD·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →